Drugs / MAX-40279
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03412292 | Aug 2018 → Nov 2022 | acute myeloid leukemia | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05395780 | Jun → Dec 2022 | gastric cancer, gastroesophageal junction adenocarcinoma | Maxinovel Pty., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAX-40279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05395780 ↗ |
| Route | Oral | “MAX-40279 is provided as a capsule for oral use” NCT03412292 ↗ |
| Target | FLT3 | “mainly target FLT3 and FGFR” NCT03412292 ↗ |